CLINICAL TRIALS PROFILE FOR MAXIPIME
✉ Email this page to a colleague
All Clinical Trials for MAXIPIME
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00609375 ↗ | Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen | Completed | Asociacion Colombiana de Infectologia, ACIN. Infectious Diseases Society of Colombia | Phase 4 | 2006-09-01 | To determine the efficacy of the administration of 7 to 14 days of cefepime in a continuous infusion vs an intermittent (every 8 hours) administration, in adult patients hospitalized in Bogotá with sepsis and bacteremia caused by gram negative bacilli. The outcome was the rate of clinical cure and microbiological cure after 7 and 14 days of initiation of therapy and rates of relapse after 28 days. Hypothesis: The administration of beta lactams in continuous infusion allows a clinical or microbiological cure greater than the intermittent administration. |
| NCT00609375 ↗ | Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen | Completed | Clinica Palermo, Bogota | Phase 4 | 2006-09-01 | To determine the efficacy of the administration of 7 to 14 days of cefepime in a continuous infusion vs an intermittent (every 8 hours) administration, in adult patients hospitalized in Bogotá with sepsis and bacteremia caused by gram negative bacilli. The outcome was the rate of clinical cure and microbiological cure after 7 and 14 days of initiation of therapy and rates of relapse after 28 days. Hypothesis: The administration of beta lactams in continuous infusion allows a clinical or microbiological cure greater than the intermittent administration. |
| NCT00609375 ↗ | Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen | Completed | Fundación San Carlos, Bogota | Phase 4 | 2006-09-01 | To determine the efficacy of the administration of 7 to 14 days of cefepime in a continuous infusion vs an intermittent (every 8 hours) administration, in adult patients hospitalized in Bogotá with sepsis and bacteremia caused by gram negative bacilli. The outcome was the rate of clinical cure and microbiological cure after 7 and 14 days of initiation of therapy and rates of relapse after 28 days. Hypothesis: The administration of beta lactams in continuous infusion allows a clinical or microbiological cure greater than the intermittent administration. |
| NCT00609375 ↗ | Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen | Completed | Hospital san Jorge, Pereira | Phase 4 | 2006-09-01 | To determine the efficacy of the administration of 7 to 14 days of cefepime in a continuous infusion vs an intermittent (every 8 hours) administration, in adult patients hospitalized in Bogotá with sepsis and bacteremia caused by gram negative bacilli. The outcome was the rate of clinical cure and microbiological cure after 7 and 14 days of initiation of therapy and rates of relapse after 28 days. Hypothesis: The administration of beta lactams in continuous infusion allows a clinical or microbiological cure greater than the intermittent administration. |
| NCT00609375 ↗ | Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen | Completed | Hospital san Juan de Dios, Antioquia | Phase 4 | 2006-09-01 | To determine the efficacy of the administration of 7 to 14 days of cefepime in a continuous infusion vs an intermittent (every 8 hours) administration, in adult patients hospitalized in Bogotá with sepsis and bacteremia caused by gram negative bacilli. The outcome was the rate of clinical cure and microbiological cure after 7 and 14 days of initiation of therapy and rates of relapse after 28 days. Hypothesis: The administration of beta lactams in continuous infusion allows a clinical or microbiological cure greater than the intermittent administration. |
| NCT00609375 ↗ | Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen | Completed | Hospital Santa Clara, Bogota | Phase 4 | 2006-09-01 | To determine the efficacy of the administration of 7 to 14 days of cefepime in a continuous infusion vs an intermittent (every 8 hours) administration, in adult patients hospitalized in Bogotá with sepsis and bacteremia caused by gram negative bacilli. The outcome was the rate of clinical cure and microbiological cure after 7 and 14 days of initiation of therapy and rates of relapse after 28 days. Hypothesis: The administration of beta lactams in continuous infusion allows a clinical or microbiological cure greater than the intermittent administration. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for MAXIPIME
Condition Name
Clinical Trial Locations for MAXIPIME
Trials by Country
Clinical Trial Progress for MAXIPIME
Clinical Trial Phase
Clinical Trial Sponsors for MAXIPIME
Sponsor Name
